Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma

PD-1 says goodbye, TIM-3 says hello

(2016) Diana Romero   Nature Reviews Clinical Oncology

Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma

(2016) ZENGJIN LIU et al.   Oncology Letters

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Anti-PD-L1 antibody active in metastatic bladder cancer

(2015) Vicki Brower   LANCET ONCOLOGY

Structural and functional features of central nervous system lymphatic vessels

(2015) Antoine Louveau et al.   NATURE

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice

(2015) Stefano Garofalo et al.   Nature Communications

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry

(2015) Pei Yang et al.   Oncotarget

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

PDL1 expression is an independent prognostic factor in localized GIST

(2015) François Bertucci et al.   OncoImmunology

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

(2015) Jiabei He et al.   Scientific Reports

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

PD-L1 expression in nonclear-cell renal cell carcinoma

(2014) T. K. Choueiri et al.   ANNALS OF ONCOLOGY

circlize implements and enhances circular visualization in R

(2014) Zuguang Gu et al.   BIOINFORMATICS

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)

(2013) Anna Sophie Berghoff et al.   CLINICAL NEUROPATHOLOGY

Cell-based Immunotherapy Against Gliomas: From Bench to Bedside

(2013) M Sarah S Bovenberg et al.   MOLECULAR THERAPY

Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group

(2012) Wei Yan et al.   NEURO-ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China

(2012) Wei Yan et al.   PLoS One

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

(2012) Laurence Zitvogel et al.   OncoImmunology

pROC: an open-source package for R and S+ to analyze and compare ROC curves

(2011) Xavier Robin et al.   BMC BIOINFORMATICS

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

(2010) E. G. Van Meir et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?

(2010) A. B. Heimberger et al.   NEURO-ONCOLOGY

The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with γ-radiation-induced T-cell lymphoblastic lymphomas

(2010) J Santos et al.   ONCOGENE